AR016423A1 - Composicion farmaceutica de un inhibidor de la aldosa reductasa y un inhibidor de la glucogeno fosforilasa, uso y equipo que contienen dichos inhibidores - Google Patents

Composicion farmaceutica de un inhibidor de la aldosa reductasa y un inhibidor de la glucogeno fosforilasa, uso y equipo que contienen dichos inhibidores

Info

Publication number
AR016423A1
AR016423A1 ARP980105883A ARP980105883A AR016423A1 AR 016423 A1 AR016423 A1 AR 016423A1 AR P980105883 A ARP980105883 A AR P980105883A AR P980105883 A ARP980105883 A AR P980105883A AR 016423 A1 AR016423 A1 AR 016423A1
Authority
AR
Argentina
Prior art keywords
alkyl
4alkyl
inhibitor
halo
trifluoromethyl
Prior art date
Application number
ARP980105883A
Other languages
English (en)
Spanish (es)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR016423A1 publication Critical patent/AR016423A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Noise Elimination (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Superheterodyne Receivers (AREA)
ARP980105883A 1997-11-21 1998-11-19 Composicion farmaceutica de un inhibidor de la aldosa reductasa y un inhibidor de la glucogeno fosforilasa, uso y equipo que contienen dichos inhibidores AR016423A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6636597P 1997-11-21 1997-11-21

Publications (1)

Publication Number Publication Date
AR016423A1 true AR016423A1 (es) 2001-07-04

Family

ID=22069038

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980105883A AR016423A1 (es) 1997-11-21 1998-11-19 Composicion farmaceutica de un inhibidor de la aldosa reductasa y un inhibidor de la glucogeno fosforilasa, uso y equipo que contienen dichos inhibidores

Country Status (38)

Country Link
EP (1) EP1032424B9 (pt)
JP (1) JP2002504478A (pt)
KR (2) KR20010032304A (pt)
CN (1) CN1279617A (pt)
AP (1) AP911A (pt)
AR (1) AR016423A1 (pt)
AT (1) ATE205403T1 (pt)
AU (1) AU733304B2 (pt)
BG (1) BG104435A (pt)
BR (1) BR9814698A (pt)
CA (1) CA2310069A1 (pt)
DE (1) DE69801680T2 (pt)
DK (1) DK1032424T3 (pt)
DZ (1) DZ2656A1 (pt)
EA (1) EA002365B1 (pt)
ES (1) ES2161548T3 (pt)
GR (1) GR3037071T3 (pt)
GT (1) GT199800166A (pt)
HR (1) HRP20000327A2 (pt)
HU (1) HUP0100272A3 (pt)
ID (1) ID24524A (pt)
IL (1) IL135713A0 (pt)
IS (1) IS5453A (pt)
MA (1) MA26568A1 (pt)
NO (1) NO20002164L (pt)
OA (1) OA11379A (pt)
PA (1) PA8462301A1 (pt)
PE (1) PE135399A1 (pt)
PL (1) PL340643A1 (pt)
PT (1) PT1032424E (pt)
SK (1) SK7222000A3 (pt)
TN (1) TNSN98211A1 (pt)
TR (1) TR200001451T2 (pt)
UA (1) UA57811C2 (pt)
UY (1) UY25258A1 (pt)
WO (1) WO1999026659A1 (pt)
YU (1) YU30700A (pt)
ZA (1) ZA9810636B (pt)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000047206A1 (en) * 1999-02-12 2000-08-17 Novo Nordisk A/S Use of pyrrolidine derivatives for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of obesity or appetite regulation
US20030139434A1 (en) 2000-01-21 2003-07-24 Bork Balkan Combinations comprising dipeptidylpeptidase-iv inhibitor
CO5271699A1 (es) 2000-01-24 2003-04-30 Pfizer Prod Inc Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa
US6570013B2 (en) 2000-02-16 2003-05-27 Pfizer Inc Salts of zopolrestat
US6395767B2 (en) * 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
IL144507A0 (en) * 2000-07-31 2002-05-23 Pfizer Prod Inc Use of glycogen phosphorylase inhibitors to inhibit tumor growth
WO2002098429A1 (en) * 2001-06-07 2002-12-12 Pfizer Products Inc. Ethanolamine, diethanolamine or triethanolamine salt of zopolrestat
GB0205170D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205162D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205165D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205176D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
US7057046B2 (en) 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use
CA2392486A1 (en) 2002-07-05 2002-12-08 Duchesnay Inc. Pharmaceutical dosage form bearing pregnancy-friendly indicia
US7098235B2 (en) 2002-11-14 2006-08-29 Bristol-Myers Squibb Co. Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
US7767828B2 (en) 2003-11-12 2010-08-03 Phenomix Corporation Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7317109B2 (en) 2003-11-12 2008-01-08 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7576121B2 (en) 2003-11-12 2009-08-18 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
WO2005047297A1 (en) 2003-11-12 2005-05-26 Phenomix Corporation Heterocyclic boronic acid compounds
US7786163B2 (en) 2004-07-12 2010-08-31 Forest Laboratories Holdings Limited (BM) Constrained cyano compounds
WO2006055463A2 (en) 2004-11-15 2006-05-26 Bristol-Myers Squibb Company 2-amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
US7226942B2 (en) 2004-11-15 2007-06-05 Bristol-Myers Squibb Company 2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
US7214704B2 (en) 2004-11-15 2007-05-08 Bristol-Myers Squibb Company 2-Amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
WO2006055435A1 (en) 2004-11-15 2006-05-26 Bristol-Myers Squibb Company 2-aminonaphthalene derivatives and related glycogen phosphorylase inhibitors
US20060235028A1 (en) 2005-04-14 2006-10-19 Li James J Inhibitors of 11-beta hydroxysteroid dehydrogenase type I
US7825139B2 (en) 2005-05-25 2010-11-02 Forest Laboratories Holdings Limited (BM) Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
CA2622608C (en) 2005-09-14 2014-08-19 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors for treating diabetes
WO2008005910A2 (en) 2006-07-06 2008-01-10 Bristol-Myers Squibb Company Pyridone/hydroxypyridine 11-beta hydroxysteroid dehydrogenase type i inhibitors
US7727978B2 (en) 2006-08-24 2010-06-01 Bristol-Myers Squibb Company Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors
US8546394B2 (en) 2007-04-17 2013-10-01 Bristol-Myers Squibb Company Substituted [1,2,4]triazolo[4,3-A]pyrazine 11-beta-hydroxysteroid dehydrogenase inhibitors
CN101668756A (zh) 2007-05-04 2010-03-10 百时美施贵宝公司 [6,6]和[6,7]-双环gpr119 g蛋白偶合受体激动剂
WO2008137436A1 (en) 2007-05-04 2008-11-13 Bristol-Myers Squibb Company [6,5]-bicyclic gpr119 g protein-coupled receptor agonists
BRPI0815097A2 (pt) 2007-07-17 2018-07-24 Bristol-Myers Squibb Company agonistas de receptor acoplado à proteína g gpr119 de piridona
TW201006821A (en) 2008-07-16 2010-02-16 Bristol Myers Squibb Co Pyridone and pyridazone analogues as GPR119 modulators
WO2011041293A1 (en) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors
PL2531501T3 (pl) 2010-02-03 2014-05-30 Takeda Pharmaceuticals Co Inhibitory kinazy 1 regulującej sygnał apoptotyczny
MX2012011460A (es) 2010-04-08 2012-11-23 Squibb Bristol Myers Co Analogos de pirimidinilpiperidiniloxipiridinona como moduladores de gpr119.
WO2011130459A1 (en) 2010-04-14 2011-10-20 Bristol-Myers Squibb Company Novel glucokinase activators and methods of using same
CA2798610A1 (en) 2010-05-06 2011-11-10 Bristol-Myers Squibb Company Bicyclic heteroaryl compounds as gpr119 modulators
US8729084B2 (en) 2010-05-06 2014-05-20 Bristol-Myers Squibb Company Benzofuranyl analogues as GPR119 modulators
ES2555927T3 (es) 2011-01-20 2016-01-11 Bionevia Pharmaceuticals Inc. Composiciones de liberación modificada de epalrestat o un derivado del mismo y métodos para el uso de las mismas
WO2013173198A1 (en) 2012-05-16 2013-11-21 Bristol-Myers Squibb Company Pyrimidinylpiperidinyloxypyridone analogues as gpr119 modulators
WO2015061272A1 (en) 2013-10-22 2015-04-30 Bristol-Myers Squibb Company Isotopically labeled triazolopyridine 11-beta hydroxysteroid dehydrogenase type i inhibitors
US10604541B2 (en) 2016-07-22 2020-03-31 Bristol-Myers Squibb Company Glucokinase activators and methods of using same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4825448A (en) * 1986-08-07 1989-04-25 International Mobile Machines Corporation Subscriber unit for wireless digital telephone system
EP0343273B1 (de) * 1988-05-27 1994-04-27 Deutsche ITT Industries GmbH Korrekturschaltung für ein digitales Quadratur-Signalpaar
US5391551A (en) * 1993-05-10 1995-02-21 Pfizer Inc. Method of lowering blood lipid levels
WO1996039384A1 (en) * 1995-06-06 1996-12-12 Pfizer, Inc. Substituted n-(indole-2-carbonyl)-glycinamides and derivatives as glycogen phosphorylase inhibitors
PT832066E (pt) * 1995-06-06 2001-12-28 Pfizer N-substituido-(indole-2-carbonil)-amidas e derivados como inibidores de glicogenio-fosforilase

Also Published As

Publication number Publication date
EP1032424B1 (en) 2001-09-12
UY25258A1 (es) 2000-12-29
PT1032424E (pt) 2001-12-28
WO1999026659A1 (en) 1999-06-03
EP1032424A1 (en) 2000-09-06
EA200000433A1 (ru) 2000-12-25
BR9814698A (pt) 2000-10-03
BG104435A (bg) 2001-01-31
TR200001451T2 (tr) 2002-06-21
PA8462301A1 (es) 2000-05-24
HRP20000327A2 (en) 2001-02-28
NO20002164D0 (no) 2000-04-27
GR3037071T3 (en) 2002-01-31
ZA9810636B (en) 2000-05-22
PE135399A1 (es) 2000-01-15
HUP0100272A3 (en) 2002-11-28
EP1032424B9 (en) 2004-10-06
PL340643A1 (en) 2001-02-12
UA57811C2 (uk) 2003-07-15
NO20002164L (no) 2000-07-19
DK1032424T3 (da) 2001-11-19
HUP0100272A2 (hu) 2001-06-28
KR20010032304A (ko) 2001-04-16
EA002365B1 (ru) 2002-04-25
TNSN98211A1 (fr) 2005-03-15
DZ2656A1 (fr) 2003-03-22
KR20010032300A (ko) 2001-04-16
SK7222000A3 (en) 2001-09-11
IS5453A (is) 2000-04-14
KR100661214B1 (ko) 2006-12-26
AP9801401A0 (en) 1998-12-31
IL135713A0 (en) 2001-05-20
AP911A (en) 2000-12-07
MA26568A1 (fr) 2004-12-20
DE69801680D1 (de) 2001-10-18
ID24524A (id) 2000-07-20
AU733304B2 (en) 2001-05-10
OA11379A (en) 2004-01-28
ATE205403T1 (de) 2001-09-15
YU30700A (sh) 2002-12-10
AU9555898A (en) 1999-06-15
ES2161548T3 (es) 2001-12-01
CA2310069A1 (en) 1999-06-03
JP2002504478A (ja) 2002-02-12
GT199800166A (es) 2000-04-19
DE69801680T2 (de) 2002-02-07
CN1279617A (zh) 2001-01-10

Similar Documents

Publication Publication Date Title
AR016423A1 (es) Composicion farmaceutica de un inhibidor de la aldosa reductasa y un inhibidor de la glucogeno fosforilasa, uso y equipo que contienen dichos inhibidores
ES2088933T3 (es) Derivados de pirazol, procedimientos para su preparacion y composicion farmaceutica que los contiene.
BR0214455A (pt) Derivados benzotiazol
AR018175A1 (es) Compuestos de indol-3-glioxilamidas sustituidas, utiles como medicamentos antitumorales, composiciones farmaceuticas formuladas con dichos derivados,utilizacion de dichos derivados para la preparacion de medicamentos antitumorales y los medicamentos asi preparados.
HU9503985D0 (en) Prodrugs of protein tyrosine kinase inhibitors
CA2529464A1 (en) Propionamide derivatives useful as androgen receptor modulators
CR10145A (es) Derivados de tropano útiles en terapia (divisional exp. 6800)
BR9907300A (pt) Inibidores do fator xa oxoaza-heterociclila substituìdos
ATE220677T1 (de) Pyrazolotriazine mit interleukin-1 und tumor necrosis faktor inhibitor wirkung
CO5011115A1 (es) Compuestos y metodos quimioquina
WO2001074331A1 (fr) Compositions huileuses contenant des medicaments solubles dans des graisses
GB0121580D0 (en) Novel compounds
BR0308145A (pt) Composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto
KR970061252A (ko) 비-심장 허혈증과 관련된 조직 손상을 감소시키기 위한 약제학적 조성물
WO2002049628A3 (en) Methods of treating anxiety disorders
FI933424A (fi) Peptidyl-4-amino-2,2-difluor-3-oxo-1,6-hexandisyraderivat som antiinflammatoriska medel
AR010050A1 (es) COMPUESTO TRICíCLICO SUSTITUIDO, COMPOSICIoN FARMACÉUTICA QUE LO COMPRENDE Y USO PARA FABRICAR UN MEDICAMENTO PARA INHIBIR SELECTIVAMENTE SPLA2
HUP0203184A2 (hu) Izoxazolkarboxamid-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
NZ507560A (en) Hydroxamic acid derivatives as antibacterials
GB9602029D0 (en) New heterocyclic compounds
CO4930276A1 (es) Nuevos derivados de aminofosfohato y proceso de prepara cion
BRPI0409465A (pt) derivados de carboxamida como agentes antidiabéticos
KR910014119A (ko) 항-고혈압 활성을 갖는 티아졸리딘 유도체 및 그의 치료용도
FI20001771A (fi) Indolijohdannaisia steroidi-5alfa-reduktaasin inhibiitoreina
ES2166043T3 (es) Uso de amlexanox en la preparacion de un medicamento para el tratamiento de ulceras aftosas.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal